Supplemental Data:

There were no statistically significant or clinically important differences in MEDFICTS and IPAQ at baseline between Ustekinumab and placebo groups:

measure	n	coef	p	95% CI	
Difference in baseline IPAQ MET	39	1619.80	0.2051	-924.77	4164.37
Difference in baseline MEDFICTS	43	-0.39	0.9626	-17.26	16.47

Supplemental Table 1. Non-Serious Adverse Events During Trial Period

Adverse Event	**Ustekinumab**	**Placebo**	**Total**
Common Cold	3 (13.64)	0	3 (6.98)
External Ear Pain*	0	1 (4.76)	1 (2.33)
Fracture*	1 (4.55)	0	1 (2.33)
Pain	0	1 (4.76)	1 (2.33)
Skin and Subcutaneous Tissue Disorders*	1 (4.55)	0	1 (2.33)
Upper Respiratory Infection	1 (4.55)	3 (14.29)	4 (9.30)
Urinary Tract Infection*	1 (4.55)	0	1 (2.33)

* Total adverse events greater than 5 percent throughout the trial

Supplemental Table 2. Non-Serious Adverse Events During Open Label Extension period

Adverse Event	**Ustekinumab**	**Placebo cross over to Ustekinumab**	**Total**
Allergies to Foods, Food Additives, Drugs	0	2 (9.52)	2 (4.65)
Anxiety	2 (9.09)	0	2 (4.65)
Back Pain	2 (9.09)	9	2 (4.65)
Common Cold	3 (13.64)	2 (9.52)	5 (11.63)
Dizziness	2 (9.09)	0	2 (4.65)
External Ear Pain*	0	1 (4.76)	1 (2.33)
Fracture*	1 (4.55)	0	1 (2.33)
Pain*	0	1 (4.76)	1 (2.33)
Skin and Subcutaneous Tissue Disorders	1 (4.55)	1 (4.76)	2 (4.65)
Upper Respiratory Infection	10 (45.45)	4 (19.05)	14 (32.56)
Urinary Tract Infection	2 (9.09)	0	2 (4.65)

* Total adverse events greater than 5 percent throughout the trial

Supplemental Figure 1: Study Schematic

Supplemental Figure 2. Patient recruitment scheme for the study.

Supplemental Figure 1: Study Schematic



Supplemental Figure 2. Patient recruitment scheme for the study.